-
Mashup Score: 0
Rami Komrokji, MD, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes, and highlights other key updates in chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and myelofibrosis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Our results suggest that G-CSF, decitabine, and busulfan–cyclophosphamide conditioning is a better choice than busulfan–cyclophosphamide conditioning for patients with myelodysplastic syndrome-RAEB or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic HSCT. This conditioning could be a suitable therapuetic option for this patient population.
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Now OF: G-CSF and decitabine plus busulfan–cyclophosphamide conditioning reduced 2-year cumulative incidence of relapse versus busulfan–cyclophosphamide in patients with MDS-RAEB or AML secondary to MDS receiving alloHSCT in a ph 3 trial. #leusm #mdsm https://t.co/AKe3FfHbTQ https://t.co/piTzIS81zF
-
-
Mashup Score: 0
Rami Komrokji, MD, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes, and highlights other key updates in chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and myelofibrosis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rami Komrokji, MD, of @MoffittNews, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes #mdsm https://t.co/p6cisSZRLn https://t.co/oJiwcMmIcg
-
-
Mashup Score: 1
Rami Komrokji, MD, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes, and highlights other key updates in chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and myelofibrosis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rami Komrokji, MD, of @MoffittNews, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes #mdsm https://t.co/rTgQLQPVyJ https://t.co/j7esAxWpjH
-
-
Mashup Score: 0
Rami Komrokji, MD, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes, and highlights other key updates in chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and myelofibrosis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rami Komrokji, MD, of @MoffittNews, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes #mdsm https://t.co/v85GQFCA9P https://t.co/GjuJunxSB9
-
-
Mashup Score: 0
Rami Komrokji, MD, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes, and highlights other key updates in chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and myelofibrosis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rami Komrokji, MD, of @MoffittNews, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes #mdsm https://t.co/uX38BHt1q7 https://t.co/n83sc6xa0u
-
-
Mashup Score: 0
Rami Komrokji, MD, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes, and highlights other key updates in chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and myelofibrosis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rami Komrokji, MD, of @MoffittNews, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes #mdsm https://t.co/hXZ8EEV7rF https://t.co/tCxgMj1iR8
-
-
Mashup Score: 0
Dan Pollyea, MD, MS, discussed the difficulties in developing new agents for the treatment of high-risk MDS, the objective of the ENHANCE trial, and the potential for other therapies to emerge in the treatment paradigm.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dan Pollyea, MD, MS, discussed the difficulties in developing new agents for the treatment of high-risk MDS, the objective of the ENHANCE trial, and the potential for other therapies to emerge in the treatment paradigm. @DanPollyea @CUMedicalSchool #mdsm https://t.co/PJtm5ifyXM
-
-
Mashup Score: 0
The FDA has granted permission for enrollment to resume in the monotherapy phase 1a portion of the phase 1/2 TakeAim Leukemia trial evaluating emavusertib in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The @US_FDA has granted permission for enrollment to resume in the monotherapy phase 1a portion of the phase 1/2 TakeAim Leukemia trial evaluating emavusertib in R/R AML or high-risk myelodysplastic syndromes. #mdsm https://t.co/BDKFSMNyIP https://t.co/dMusi4fYZn
-
-
Mashup Score: 0
Dan Pollyea, MD, MS, discussed the difficulties in developing new agents for the treatment of high-risk MDS, the objective of the ENHANCE trial, and the potential for other therapies to emerge in the treatment paradigm.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: @DanPollyea discussed the difficulties in developing new agents for the treatment of high-risk MDS, the objective of the ENHANCE trial, and the potential for other therapies to emerge in the treatment paradigm. @CUMedicalSchool #mdsm https://t.co/SZKLlx2Zhg
-
Rami Komrokji, MD, of @MoffittNews, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes #mdsm https://t.co/HxvoK6dctm https://t.co/mxaOMBaacx